It’s Never Too Late in Life to Toke: Tilray (TLRY) Releases “Medical Cannabis in Older Patients Study” Findings

Tilray Medical, a division of Tilray Brands, Inc. (TLRY) and a global leader in medical cannabis, announced a new scientific publication titled, “Medical Cannabis for Patients Over Age 50: A Multi-Site, Prospective Study of Patterns of Use and Health Outcomes.” This study, known as the Medical Cannabis in Older Patients Study (MCOPS), is a multi-site, prospective, observational study examining the real-world impact of medical cannabis on patients over the age of 50 under the guidance of healthcare providers.

The MCOPS study included 299 participants with an average age of 66.7 years and whom ~90% used medical cannabis to treat pain and arthritis. The study highlights the impact of medical cannabis on health outcomes, particularly focusing on pain, sleep, and quality of life.

Under medical guidance, the MCOPS study showed correlations with improvements in pain scores, sleep, and quality of life for a growing subset of patients. A significant reduction in the use of co-medications was observed, indicating that treatment with medical cannabis can be a cost-effective option for this population.

José Tempero, Tilray’s Medical Director, stated, “Our involvement in this initiative underscores our unwavering commitment to advancing medical research and highlights our dedication to providing products that support these findings. This comprehensive research brings us one step closer to unlocking the full therapeutic potential of medical cannabis, especially reinforcing its role as a treatment option for an aging population.”

Tilray currently leads the PRISM Cannabis Index.